Novartis is a pharmaceuticals, consumer health, generics, eye-care, and animal health company. Its main business units are Pharmaceuticals, Vaccines and Diagnostics, Sandoz and Consumer Health. 
The Pharmaceuticals business remains its biggest and most profitable business. Strong growth was shown by the cardiovascular and oncology franchises. However, it sees its main challenge as ‘keeping a sharp eye on the market evolution’.
Novartis has a strategy of consistent investment in R&D, enabling it to bring to market innovative and differentiated products that offer patients clear therapeutic benefits. It is expanding its generics business to provide affordable treatment options following patent expiries and it is developing promising new growth platforms such as vaccines to reduce healthcare costs through disease prevention.
Headquartered in Basel, Switzerland, Novartis employs over 96,717 people and achieved sales of $41bn in 2008.
ICIS Chemical Business magazine has unveiled the ICIS Top 100 Chemical Companies, with rankings based on 2008 sales.
A PDF of the ICIS Top 100 Chemical Companies is available for download on ICIS connect.
See the article and analysis of the ICIS Top 100 on ICIS news.
Key Personnel
Chairman and CEO: Daniel Vasella
Deputy CFO and CFO designate: Jonathan Symonds
Chief financial officer: Raymund Breu (retires 31/03/2010)
Vice chairman and lead director: Ulrich Lehner
Vice chairman: Hans-Jorg Rudloff
Board member: Peter Burckhardt
Board member: Srikant Datar
Board member: William George
Board member: Alexandre Jetzer
Board member: Pierre Landolt
Board member: Andreas von Planta
Board member: Wendelin Wiedeking
Board member: Marjorie Yang
Board member: Rolf Zinkernagel
Board member: Ann Fudge
(Updated September 2009)
Contacts
Novartis International AG
CH-4002 Basel
Switzerland
Tel: +41 61 324 1111
Fax: +41 61 324 8001
www.novartis.com
Novartis
Company Structure
Novartis is a pharmaceuticals, consumer health, generics, eye-care, and animal health company. Novartis was created by the merger of Ciba-Geigy and Sandoz in 1996. In 2000, it spun off its crop protection and seeds sector and merged it with the agrochemicals business of AstraZeneca.
More about Novartis Structure
Novartis
Strategy & Financial Highlights
The core elements of Novartis’s strategy are focused mainly on innovation and patient needs. Novartis also has a strategy of consistent investment in R&D, enabling it to bring to market innovative and differentiated products that offer patients clear therapeutic benefits.(Edited from: Annual Report). ICIS also provides you with key financial data listed in table form.
More about Novartis Strategy & Financial Highlights
News:
Get news on Novartis plus the latest chemical news, information, data, market movements and analysis
in one place with ICIS news
Search:
Find details on other chemical companies and suppliers with
ICIS search
Newsletters:
ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.
Plants and projects:
Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database